NRG-BN010: A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma

Publication Date

11-17-2022

Presented At:

SNO Annual Meeting

Content Type

Presentation

This document is currently not available here.

Share

COinS